Furthermore, the coexpression of the CCL2 receptor CCR2b [29] or CXCL9 [30] in CAR-T cells can enhance the infiltration and tumor killing ability of CAR-T cells, which can lead to improved tumor control and potentially enhance the efficacy of synergistic therapies involving radiotherapy and immunotherapy. Here, CCL2 is linked to neoplasm.